EpiCast Report on Renal Cell Carcinoma Industry Analysis and Epidemiology Forecast to 2023
Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=222343
GlobalData epidemiologists forecast that there were 186,179 incident cases of RCC in the 8MM in 2013, and the number of incident cases will grow 6.25% over the next decade to 302,449 incident cases. In 2013, there were 593,228 prevalent cases of RCC in the 8MM. Each of the 8MM will see an increase in prevalent cases over the 10-year forecast period.
This forecast is supported by ageand sex-specific data for the incidence. The oneto five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. Additionally, in each of the 8MM, the analysis is strengthened by the use of a consistent methodology for the diagnosed incident cases forecast, using regression techniques, and is based on 15 years of country-specific historical data points pertaining to the ageand sex-specific diagnosed incidence of RCC.
Scope
The Renal Cell Carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC segmented by sex and age (in five-year age groups beginning at 20 years and ending at 85 years and older).
GlobalData epidemiologists also forecast the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, the report provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.
The RCC epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Browse Detail Report With TOC @ http://www.researchmoz.us/epicast-report-renal-cell-carcinoma-epidemiology-forecast-to-2023-report.html
Reasons to buy
Develop business strategies by understanding the trends shaping and driving the global RCC market.
Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RCC therapeutics in each of the markets covered.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=222343
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG